BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19674832)

  • 21. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
    Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
    BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.
    Eissa S; Swellam M; El-Khouly IM; Kassim SK; Shehata H; Mansour A; Esmat M; Nossier AI; Hamdy MA; Awad NM; El-Ahmady O
    Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1657-64. PubMed ID: 21680534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.
    García-Baquero R; Puerta P; Beltran M; Alvarez M; Sacristan R; Alvarez-Ossorio JL; Sánchez-Carbayo M
    J Urol; 2013 Aug; 190(2):723-30. PubMed ID: 23485510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
    Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
    J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
    Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
    BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
    Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
    J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
    Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
    J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
    Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
    Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARβ) and survivin genes in tumor tissues and voided urine of bladder cancer patients.
    Berrada N; Amzazi S; Ameziane El Hassani R; Benbacer L; El Mzibri M; Khyatti M; Chafiki J; Abbar M; Al Bouzidi A; Ameur A; Attaleb M
    Cell Mol Biol (Noisy-le-grand); 2012 Sep; Suppl.58():OL1744-51. PubMed ID: 22992440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
    Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
    Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
    Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
    Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA Hypermethylation af a Panel Of Genes as an Urinary Biomarker For Bladder Cancer Diagnosis.
    Georgopoulos P; Papaioannou M; Markopoulou S; Fragou A; Kouvatseas G; Apostolidis A
    Urol J; 2021 Nov; 19(3):214-220. PubMed ID: 34806159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma.
    Tsou JA; Galler JS; Siegmund KD; Laird PW; Turla S; Cozen W; Hagen JA; Koss MN; Laird-Offringa IA
    Mol Cancer; 2007 Oct; 6():70. PubMed ID: 17967182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.